Catalent (NYSE:CTLT) quickly rose 1% after a report that the contract drug manufacturer's $16.5 billion sale to Novo Holdings ...

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...

Novo Holdings, the investment arm of the Novo Nordisk Foundation, has gained approval from the European Commission (EC) for ...

In the U.S., the chorus of opposition against the proposed buyout continues to grow and now includes the CEOs of Roche and ...

By far, the largest acquisition of 2024 was Novo Holdings' yet-to-be-closed buyout of manufacturer Catalent at $16.5 billion.

The BIOSECURE Act, which would restrict drugmakers from using key Chinese contract manufacturers, was left out of a defense ...

Years of layoffs and alleged mismanagement have left employees “sick” of the pharmaceutical contract manufacturer Catalent, ...

The European Commission on Friday unconditionally approved a controversial deal in which Novo Holdings, the parent company of ...

Novo Holdings’ $16.5 billion takeover of US contract development and manufacturing organisation (CDMO) Catalent does not ...

BRUSSELS (Reuters) -Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S.

Bioprocessing technology has a role to play in helping developers exert greater control over production processes.

As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have ...